Previous 10 | Next 10 |
NK cells engineered with a high-affinity CD16 receptor have the potential to enhance monoclonal antibody therapeutic effects against cancer cells Combination monoclonal antibody therapy and CD16 NK-92 cell therapy patent term to 2036 ImmunityBio, Inc. ( NASDAQ: IBRX ...
AMYRIS AND IMMUNITYBIO COMPLETE JOINT VENTURE FOR NEXT GENERATION COVID-19 RNA VACCINE PR Newswire EMERYVILLE , Calif. and CULVER CITY, Calif. , Jan. 3, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company acce...
Gainers: Altamira Therapeutics (NASDAQ:CYTO) +21%, Regencell Bioscience (NASDAQ:RGC) +17%, BridgeBio Pharma BBIO +13%, ImmunityBio (NASDAQ:IBRX) +8%, BiondVax Pharmaceuticals BVXV +8%. Losers: Biofrontera (NASDAQ:BFRI) -21%, Microbot Medical (...
ImmunityBio is preparing to submit their BLA in NMIBC in the first quarter of 2022. The company is moving forward with several COVID-19 vaccine programs with different technologies. The company recently secured $300M in new debt financing from Dr. Patrick Soon-Shiong’s NantCapi...
Year-End Review: SISONKE Universal Boost COVID T-Cell vaccine trial initiates Phase 3 enrollment in South Africa in previously vaccinated participants Increased GMP manufacturing capacity for RNA, DNA, Subunit Proteins, and Adjuvants vaccine platforms in U.S., South Africa...
ImmunityBio (IBRX +15.0%) has recorded its biggest-ever intraday gain on the news of a licensing deal with the Australian biopharmaceutical company EnGeneIC for a COVID-19 vaccine and cancer therapy. Per the terms, ImmunityBio (NASDAQ:IBRX) will obtain an exclusive, worldwide license from EnG...
Second-generation vaccines that combine different advanced DNA, RNA, Protein, and Adjuvant components are critical to providing accessible, broad, and durable protection against current and future likely SARS-CoV-2 variants By adding self-amplifying self-adjuvating RNA (SASA-RNA),...
Amyris (NASDAQ:AMRS) has entered into a 50:50 joint venture arrangement with ImmunityBio (NASDAQ:IBRX) to accelerate the commercialization of its COVID-19 vaccine. The parties have signed a binding term sheet, and a definitive agreement is in process and is expected to be executed within the ...
Amyris Announces JV Partnership With ImmunityBio For Next Generation COVID-19 RNA Vaccine PR Newswire EMERYVILLE, Calif. , Nov. 8, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to susta...
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that Founder, Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong, M.D., will deliver a company presentation at the 2021 Jefferies London Healthcare Conferenc...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 01:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ImmunityBio, Inc. (NasdaqGS: IBRX). On May 11, 2023, the Company disclosed that it had receiv...